What is "tesofensine"

n. A phenyltropane drug under development for the treatment of obesity.

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.

As of 2015, tesofensine has been discontinued for the treatment of Alzheimer's disease; Parkinson's disease and is in Phase II clinical trials for obesity.1